Pharming Group to participate in March investor conference
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) has announced its participation in the upcoming 37th Annual Roth Conference in Dana Point, California, scheduled for March 16-18, 2025.
The company's Chief Medical Officer Anurag Relan and VP Investor Relations and Corporate Communications Michael Levitan will engage in a fireside chat and Q&A session on March 17, 2025, at 1:30 PM PT/21:30 CET.
Investors interested in one-on-one meetings with Pharming's management team can arrange appointments through the company's Investor Relations team or their Roth representative.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) ha annunciato la sua partecipazione alla prossima 37ª Conferenza Annuale Roth a Dana Point, California, in programma dal 16 al 18 marzo 2025.
Il Chief Medical Officer dell'azienda, Anurag Relan, e il VP delle Relazioni con gli Investitori e Comunicazioni Aziendali, Michael Levitan, parteciperanno a una chiacchierata informale e a una sessione di domande e risposte il 17 marzo 2025, alle 13:30 PT/21:30 CET.
Gli investitori interessati a incontri individuali con il team di gestione di Pharming possono organizzare appuntamenti attraverso il team delle Relazioni con gli Investitori dell'azienda o il loro rappresentante Roth.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) ha anunciado su participación en la próxima 37ª Conferencia Anual Roth en Dana Point, California, programada del 16 al 18 de marzo de 2025.
El Director Médico de la compañía, Anurag Relan, y el VP de Relaciones con Inversores y Comunicaciones Corporativas, Michael Levitan, participarán en una charla informal y una sesión de preguntas y respuestas el 17 de marzo de 2025, a la 1:30 PM PT/21:30 CET.
Los inversores interesados en reuniones uno a uno con el equipo de gestión de Pharming pueden concertar citas a través del equipo de Relaciones con Inversores de la empresa o su representante de Roth.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR)는 2025년 3월 16일부터 18일까지 캘리포니아 다나포인트에서 열리는 제37회 연례 로스 컨퍼런스에 참가할 것이라고 발표했습니다.
회사의 최고 의료 책임자인 Anurag Relan과 투자자 관계 및 기업 커뮤니케이션 부사장인 Michael Levitan은 2025년 3월 17일 오후 1시 30분 PT/오후 9시 30분 CET에 진행되는 대화 및 Q&A 세션에 참여할 예정입니다.
Pharming 경영진과의 일대일 회의에 관심이 있는 투자자는 회사의 투자자 관계 팀이나 Roth 대표를 통해 약속을 조정할 수 있습니다.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) a annoncé sa participation à la prochaine 37e Conférence Annuelle Roth à Dana Point, Californie, prévue du 16 au 18 mars 2025.
Le Directeur Médical de l'entreprise, Anurag Relan, et le VP des Relations Investisseurs et Communications d'Entreprise, Michael Levitan, participeront à une discussion informelle et à une session de questions-réponses le 17 mars 2025 à 13h30 PT/21h30 CET.
Les investisseurs intéressés par des réunions individuelles avec l'équipe de direction de Pharming peuvent organiser des rendez-vous via l'équipe des Relations Investisseurs de l'entreprise ou leur représentant Roth.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) hat seine Teilnahme an der bevorstehenden 37. jährlichen Roth-Konferenz in Dana Point, Kalifornien, die vom 16. bis 18. März 2025 stattfindet, angekündigt.
Der Chief Medical Officer des Unternehmens, Anurag Relan, und der VP für Investor Relations und Unternehmenskommunikation, Michael Levitan, werden am 17. März 2025 um 13:30 Uhr PT/21:30 Uhr CET an einem informellen Gespräch und einer Q&A-Session teilnehmen.
Investoren, die an persönlichen Gesprächen mit dem Management-Team von Pharming interessiert sind, können Termine über das Investor Relations-Team des Unternehmens oder ihren Roth-Vertreter vereinbaren.
- None.
- None.
Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of March:
- 37th Annual Roth Conference, Dana Point, CA, USA, March 16-18, 2025
Anurag Relan, Chief Medical Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Monday, March 17 at 01:30pm PT/21:30 CET.
For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Roth representative.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, United Kingdom
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
FAQ
When is Pharming Group (PHARM) presenting at the 37th Annual Roth Conference 2025?
Which Pharming Group executives will attend the Roth Conference 2025?
How can investors schedule meetings with Pharming Group (PHARM) management at the Roth Conference?
Where will the 37th Annual Roth Conference featuring Pharming Group (PHARM) take place?
What type of presentation will Pharming Group (PHARM) deliver at the Roth Conference?
